NVS - Novartis AG

NYSE - Nasdaq Real Time Price. Currency in USD
89.38
-0.10 (-0.11%)
As of 2:17PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close89.47
Open90.17
Bid89.39 x 1000
Ask89.41 x 1200
Day's Range89.26 - 90.17
52 Week Range72.73 - 95.00
Volume682,010
Avg. Volume2,117,406
Market Cap205.194B
Beta (3Y Monthly)0.55
PE Ratio (TTM)18.36
EPS (TTM)4.87
Earnings DateN/A
Forward Dividend & Yield2.83 (3.17%)
Ex-Dividend Date2019-03-04
1y Target Est101.00
Trade prices are not sourced from all markets
  • AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA
    Zacks

    AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

    AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.

  • 5 Biggest New Drug Approvals Potentially on the Way in 2019
    Motley Fool

    5 Biggest New Drug Approvals Potentially on the Way in 2019

    FDA approvals for these drugs could translate to billions of dollars for a few companies.

  • Novartis to answer U.S. Senate demand for data manipulation details
    Reuters

    Novartis to answer U.S. Senate demand for data manipulation details

    Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval. Novartis, which won approval for Zolgensma in May -- more than a month before it told the Food and Drug Administration of the alleged data fraud -- has terminated several scientists amid an internal investigation.

  • Financial Times

    Novartis faces further fallout over Zolgensma

    earlier this month that Novartis was facing possible civil or criminal charges over manipulated data in early stage testing of the drug on animals, sending shares down 3 per cent that day. The transaction, worth about $944,000, was executed on July 19 by an unnamed individual, according to a regulatory filing at the Swiss stock exchange. The filing says it was carried out by an “executive member of the board of directors” or a “member of the executive committee”. Novartis said the share sale was not related to Zolgensma.

  • Novartis executive sold shares before drug data manipulation made public
    Reuters

    Novartis executive sold shares before drug data manipulation made public

    An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated. Novartis announced the stock sale by an executive member of the board of directors or a member of the executive committee in a Swiss stock exchange filing dated July 19. The sale was made after the company had informed the FDA about the data manipulation but before the FDA announced it publically on Aug 6.

  • Motley Fool

    A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis

    What Novartis' misstep means to investors, plus how Exact Sciences is trying to lock up the genetic testing market.

  • AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
    Zacks

    AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL

    The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.

  • Gene therapies to test FDA's approach to regulating drugs after launch, experts say
    American City Business Journals

    Gene therapies to test FDA's approach to regulating drugs after launch, experts say

    "If the products that the (FDA) is approving aren't standing the test of time, are they going to become more tentative with drug approvals? (Cell and gene therapies) may bring that issue to the forefront," one regulatory expert said.

  • Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future
    American City Business Journals

    Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future

    The Florida startup has Bay Area investors and is aiming straight at people willing to pay thousands of dollars to beat cancer in the future.

  • Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
    Zacks

    Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat

    Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.

  • Reuters

    Novartis replaces top scientists at Avexis after drug data manipulated

    Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.

  • Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data
    Investor's Business Daily

    Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data

    Swiss pharma giant Novartis reportedly fired two scientists at its AveXis unit for manipulating data necessary to gain approval of gene therapy Zolgensma, CNBC reported Wednesday.

  • Reuters

    UPDATE 2-Novartis replaces top scientists at Avexis after drug data manipulated

    Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.

  • Barrons.com

    Everyone’s Mad At Novartis. But the Stock Is Doing Just Fine

    Public pressure is heating up on Novartis A.G. over how the company handled a data manipulation issue, but the stock is doing just fine, thanks.

  • Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%
    Zacks

    Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%

    Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.

  • Wednesday’s Vital Data: Amgen, American Airlines and Apple
    InvestorPlace

    Wednesday’s Vital Data: Amgen, American Airlines and Apple

    The topsy-turvy ride for stock traders continues this morning with U.S. stock futures pointing toward a sizeable down gap at the open. Yesterday's gains are being completely unwound.Source: Shutterstock Heading into the open, futures on the Dow Jones Industrial Average are down 1.46%, and S&P 500 futures are lower by 1.42%. Nasdaq-100 futures have lost 1.57%.In the options pits, call volume spiked sharply yesterday underlying the excitement surrounding the market rally. Specifically, about 19.9 million calls and 17.5 million puts changed hands on the session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe enthusiasm was felt at the CBOE as well, with the single-session equity put/call volume ratio falling to 0.66. Meanwhile, the 10-day moving average held its ground at 0.74. Based on the wickedness of today's open, however, I suspect both metrics to end with bearish readings today.Options traders came after calls throughout the session, boosting volumes in Amgen (NYSE:AMGN), American Airlines Group (NYSE:AAL) and Apple (NASDAQ:AAPL).Let's take a closer look: Amgen (AMGN)The direction of Amgen shares reversed in a big way this week after the biotech behemoth won a patent dispute against Novartis (NYSE:NVS). Over the past three sessions, AMGN stock has rocketed 12% higher on massive volume. The rally pushed shares back to last year's highs, and they now stand a whisper from breaking out to record levels. * 15 Growth Stocks to Buy for the Long Haul In the short run, AMGN is extended and deserving of a breather. Consolidation or a pullback will allow its moving averages to catch-up and make for a more sustainable uptrend. That said, any weakness should be viewed as a buying opportunity.On the options trading front, traders went cuckoo for calls. Activity ballooned to 1,314% of the average daily volume, with 275,296 total contracts traded; 96% of the trading came from call options alone. The catalyst for such a groundswell in call demand is the company's looming ex-dividend date. Amgen's next quarterly payment of $1.45 will be paid out to shareholders of record and investors used call options to snatch-up short-term control of the stock to gain access to the payout.Implied volatility has been falling this week and now sits at 24% or the 29th percentile of its one-year range. Premiums are baking in daily moves of $3.08 or 1.5%, so set your expectations accordingly. American Airlines (AAL)The news was light for American Airlines Group, but that didn't prevent traders from swarming its options. In an otherwise ordinary day, we saw options activity jump to 270% of the average daily volume, with 107,237 total contracts traded. Calls slightly outpaced puts to claim 55% of the session's sum.Ever since last month's earnings took the wind out of its sails, AAL stock has been declining. It has now lost 21% in three weeks and will soon test its 52-week low at $27.02. Of course, weakness isn't new for AAL. It has been in a cyclical decline for two years and has already lost over 53% of its value. Until we see resistance levels breached, buyers should cast their lines elsewhere. There are much more attractive fish to catch.Implied volatility remains, tucked near the middle of its 2019 range. It's at 41% or the 31st percentile, and premiums are pricing in daily moves of 71 cents or 2.6%. Apple (AAPL)Apple stock led the charge during Tuesday's roaring rally in the Nasdaq for one simple reason. It dodged Chinese tariffs for this year's iPhones. Here's the skinny if you want all the details.Before we get too excited over yesterday's jump, keep in mind the overnight whacking for stocks is taking a bite out of Apple's gains. The stock is set to open down 2.4%. Time will tell if the positive news is enough to keep AAPL stock aloft while the rest of the market grapples with growing recession concerns. * 7 Stocks the Insiders Are Buying on Sale The post-earnings slide found support at $192.50, so that's the line in the sand to watch. If broken, this year's ascent is in a heap of trouble. Until then, ignore the chop and focus on the bigger picture, which still points higher.On the options trading front, traders favored calls throughout the day. Total activity swelled to 137% of the average daily volume, with 686,707 contracts traded. Calls added 59% to the day's take.With uncertainty easing, implied volatility sunk to 29% or the 35th percentile of its one-year range. That means traders are now pricing in daily movement of $3.87 or 1.9%.As of this writing, Tyler Craig didn't hold a position in any of the aforementioned securities. Check out his recently released Bear Market Survival Guide to learn how to defend your portfolio against market volatility. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 The post Wednesday's Vital Data: Amgen, American Airlines and Apple appeared first on InvestorPlace.

  • Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
    Zacks

    Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study

    Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.

  • Novartis names Bulto as new head of U.S. drugs business
    Reuters

    Novartis names Bulto as new head of U.S. drugs business

    Swiss drugmaker Novartis has named company veteran Victor Bulto as head of its U.S. pharmaceuticals business, effective on Sept. 1. The statement said Chouraqui had "consistently demonstrated strong leadership, ethics and integrity" during his tenure. Bulto, who will report to Marie France Tschudin, global president of Novartis Pharmaceuticals, is a 14-year company veteran who has worked across every therapeutic area at the group and helped launch several products, including top-selling inflammation drug Cosentyx in the U.S. market.

  • Financial Times

    Novartis ousted scientists before reporting drug data manipulation

    The news of the timing of the administrative leave comes after analysts and politicians have raised questions about whether Novartis should have informed the FDA before it approved the drug on May 28. The company waited another month, until it had completed an internal investigation and the drug was approved, to tell the FDA.

  • Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales
    Investor's Business Daily

    Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales

    Amgen stock is the IBD Stock Of The Day after the biggest biotech company prevailed in a patent battle against Novartis subsidiary Sandoz, protecting nearly $5 billion in 2019 U.S. sales.

  • Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
    Zacks

    Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate

    Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.